Preclinical evaluation demonstrates accurate CD163 PET targeting in head and neck squamous cell carcinoma, suggesting noninvasive monitoring of tumor-associated macrophage dynamics.
Cu-ICT-01 demonstrated accurate targeting of CD163 in both mouse tumor models and human HNSCC tissues. CD163 PET has great potential to be a noninvasive biomarker to measure TAM activities within TME, monitor treatment response, and optimize treatment strategy.
No takes yet. Share an insight, caveat, or question.
Heo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: